Spero Therapeutics, a bacterial infection treatment developer based on research at Harvard Medical School, has filed to raise up to $86.3m in an initial public offering.
Spero Therapeutics, a US-based bacterial infection therapy developer backed by spinout-focused investment firm Osage University Partners has filed for an $86.3m initial public offering.
Founded in 2013, Spero is developing therapeutics, some based on its Potentiator Platform technology, which will enhance the potency of existing antibiotics in order to treat bacterial infections that have proven resistant to multiple drugs.
The company was co-founded by Partners Innovation Fund (PIF), a subsidiary of care provider Partners Healthcare, and Atlas Venture to exploit…
